VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patient presents with acute coronary syndrome      │ Patient presents with acute coronary syndrome      │     100 │
│ (ACS) or stable coronary artery disease (CAD)      │ (ACS) or stable coronary artery disease (CAD)      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is eligible for PCI                        │ Patient is eligible for PCI                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is willing and able to provide informed    │ Patient is willing and able to provide informed    │     100 │
│ written consent                                    │ written consent                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient not able to receive 12 months of dual      │ Patient not able to receive 12 months of dual      │     100 │
│ anti-platelet therapy                              │ anti-platelet therapy                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Failure of index PCI                               │ Failure of index PCI                               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient or physician refusal to enroll in the      │ Patient or physician refusal to enroll in the      │     100 │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with known CYP2C19 genotype prior to       │ Patient with known CYP2C19 genotype prior to       │     100 │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Planned revascularization of any vessel within 30  │ Planned revascularization of any vessel within 30  │     100 │
│ days post-index procedure and/or of the target     │ days post-index procedure and/or of the target     │         │
│ vessel(s) within 12 months post-procedure          │ vessel(s) within 12 months post-procedure          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticipated discontinuation of clopidogrel or      │ Anticipated discontinuation of clopidogrel or      │     100 │
│ ticagrelor within the 12 month follow up period,   │ ticagrelor within the 12 month follow up period,   │         │
│ example for elective surgery                       │ example for elective surgery                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of intracranial hemorrhage                 │ History of intracranial hemorrhage                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to clopidogrel or           │ Known hypersensitivity to clopidogrel or           │     100 │
│ ticagrelor or any of its components                │ ticagrelor or any of its components                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is participating in an investigational     │ Patient is participating in an investigational     │     100 │
│ drug or device clinical trial that has not reached │ drug or device clinical trial that has not reached │         │
│ its primary endpoint                               │ its primary endpoint                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient previously enrolled in this study          │ Patient previously enrolled in this study          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is pregnant, lactating, or planning to     │ Patient is pregnant, lactating, or planning to     │     100 │
│ become pregnant within 12 months                   │ become pregnant within 12 months                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has received an organ transplant or is on  │ Patient has received an organ transplant or is on  │     100 │
│ a waiting list for an organ transplant             │ a waiting list for an organ transplant             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is receiving or scheduled to receive       │ Patient is receiving or scheduled to receive       │     100 │
│ chemotherapy within 30 days before or after the    │ chemotherapy within 30 days before or after the    │         │
│ procedure                                          │ procedure                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is receiving immunosuppressive therapy or  │ Patient is receiving immunosuppressive therapy or  │     100 │
│ has known immunosuppressive or autoimmune disease  │ has known immunosuppressive or autoimmune disease  │         │
│ (e.g., human immunodeficiency virus, systemic      │ (e.g., human immunodeficiency virus, systemic      │         │
│ lupus erythematous, etc.)                          │ lupus erythematous, etc.)                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is receiving chronic oral anticoagulation  │ Patient is receiving chronic oral anticoagulation  │     100 │
│ therapy (i.e., vitamin K antagonist, direct        │ therapy (i.e., vitamin K antagonist, direct        │         │
│ thrombin inhibitor, Factor Xa inhibitor)           │ thrombin inhibitor, Factor Xa inhibitor)           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant use of potent CYP3A4 inhibitors        │ Concomitant use of potent CYP3A4 inhibitors        │     100 │
│ (atazanavir, clarithromycin, indinavir,            │ (atazanavir, clarithromycin, indinavir,            │         │
│ itraconazole, ketoconazole, nefazodone,            │ itraconazole, ketoconazole, nefazodone,            │         │
│ nelfinavir, ritonavir, saquinavir, telithromycin   │ nelfinavir, ritonavir, saquinavir, telithromycin   │         │
│ and voriconazole) or inducers (carbamazepine,      │ and voriconazole) or inducers (carbamazepine,      │         │
│ dexamethasone, phenobarbital, phenytoin, rifampin, │ dexamethasone, phenobarbital, phenytoin, rifampin, │         │
│ and rifapentine)                                   │ and rifapentine)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Non-cardiac condition limiting life expectancy to  │ Non-cardiac condition limiting life expectancy to  │     100 │
│ less than one year, per physician judgment (e.g.   │ less than one year, per physician judgment (e.g.   │         │
│ cancer)                                            │ cancer)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known history of severe hepatic impairment         │ Known history of severe hepatic impairment         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has a history of bleeding diathesis or     │ Patient has a history of bleeding diathesis or     │     100 │
│ coagulopathy or will refuse blood transfusions     │ coagulopathy or will refuse blood transfusions     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has an active pathological bleeding, such  │ Patient has an active pathological bleeding, such  │     100 │
│ as active gastrointestinal (GI) bleeding           │ as active gastrointestinal (GI) bleeding           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to take aspirin at a dosage of 100 mg or │ Inability to take aspirin at a dosage of 100 mg or │     100 │
│ less                                               │ less                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current substance abuse (e.g., alcohol, cocaine,   │ Current substance abuse (e.g., alcohol, cocaine,   │     100 │
│ heroin, etc.)                                      │ heroin, etc.)                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient \>18 years of age                          │ Patient >18 years of age                           │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine \>2.5 mg/dL within 7 days of      │ Serum creatinine >2.5 mg/dL within 7 days of index │      99 │
│ index procedure                                    │ procedure                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count \<80,000 or \>700,000 cells/mm3, or │ Platelet count <80,000 or >700,000 cells/mm3, or   │      99 │
│ white blood cell count \<3,000 cells/mm3 if        │ white blood cell count <3,000 cells/mm3 if         │         │
│ persistent (at least 2 abnormal values) within 7   │ persistent (at least 2 abnormal values) within 7   │         │
│ days prior to index procedure                      │ days prior to index procedure                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant use of simvastatin/lovastatin \> 40 mg │ Concomitant use of simvastatin/lovastatin > 40 mg  │      99 │
│ qd                                                 │ qd                                                 │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ 3 Exclusion                       │ Failure of index PCI                               │      26 │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inclusion                         │ Failure of index PCI                               │      28 │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Inability to take aspirin at a dosage of 100 mg or │      43 │
│                                   │ less                                               │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═══════════════════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                             │ CHIA Criteria   │   Score │
╞═══════════════════════════════════════════════╪═════════════════╪═════════╡
│ Patient presents with acute coronary syndrome │ NA              │       2 │
│ (ACS) or stable coronary artery disease (CAD) │                 │         │
╘═══════════════════════════════════════════════╧═════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 90.72727272727273
OverAll Ratio: 94.86363636363637
